BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 30351999)

  • 1. BRAF Inhibition in
    Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
    J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Andrews LJ; Thornton ZA; Saincher SS; Yao IY; Dawson S; McGuinness LA; Jones HE; Jefferies S; Short SC; Cheng HY; McAleenan A; Higgins JPT; Kurian KM
    Neuro Oncol; 2022 Apr; 24(4):528-540. PubMed ID: 34718782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
    Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
    N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabrafenib plus trametinib in patients with BRAF
    Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.
    Schreck KC; Strowd RE; Nabors LB; Ellingson BM; Chang M; Tan SK; Abdullaev Z; Turakulov R; Aldape K; Danda N; Desideri S; Fisher J; Iacoboni M; Surakus T; Rudek MA; Bettegowda C; Grossman SA; Ye X
    Clin Cancer Res; 2024 May; 30(10):2048-2056. PubMed ID: 38446982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
    Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
    N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF
    Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
    ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
    Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
    Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Dabrafenib in Pediatric Patients with
    Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
    Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
    Kai Z; Dingyang L; Zhuanyi Y
    World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.